U.S. License Holder:
Novimmune S.A.
Date of License:
November-20-2018
Last Update:
July-15-2025
FDA-Approved Indications
GAMIFANT (emapalumab-lzsg) is an interferon gamma (IFN-gamma) neutralizing antibody indicated for the treatment of:
Adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy;
Adult and pediatric (newborn and older) patients with HLH/macrophage activation syndrome (MAS) in known or suspected Still's disease. including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.
